Relay Therapeutics Announces Proposed Public Offering of Common Stock
2024年9月10日 - 5:34AM
Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision
medicine company transforming the drug discovery process by
combining leading-edge computational and experimental
technologies, announced today that it has commenced an
underwritten public offering of $200 million of shares of its
common stock. Relay Therapeutics also intends to grant the
underwriters a 30-day option to purchase up to an additional
fifteen percent (15%) of the shares of common stock offered in the
public offering. All of the shares in the proposed offering are to
be sold by Relay Therapeutics.
Goldman Sachs & Co. LLC, TD Cowen, Stifel and BofA
Securities are acting as joint book-running managers for the
proposed offering. Raymond James is acting as co-manager. The
offering is subject to market and other conditions, and there can
be no assurance as to whether or when the offering may be
completed, or as to the actual size or terms of the offering.
The shares of common stock are being offered by Relay
Therapeutics pursuant to an effective shelf registration statement
that was previously filed with the U.S. Securities and Exchange
Commission (SEC). A preliminary prospectus supplement and
accompanying prospectus relating to and describing the terms of the
offering will be filed with the SEC and may be obtained, when
available, from: Goldman Sachs & Co. LLC, Prospectus
Department, 200 West Street, New York, NY 10282, telephone:
1-866-471-2526, facsimile: 212-902-9316 or by email at
Prospectus-ny@ny.email.gs.com; TD Securities (USA) LLC, 1
Vanderbilt Avenue, New York, NY 10017, by telephone at (855)
495-9846 or by email at TD.ECM_Prospectus@tdsecurities.com; Stifel,
Nicolaus & Company, Incorporated, Attention: Syndicate, One
Montgomery Street, Suite 3700, San Francisco, California 94104, by
telephone at 415-364-2720 or by email at syndprospectus@stifel.com;
BofA Securities, NC1-022-02-25, 201 North Tryon Street, Charlotte,
North Carolina 28255-0001, Attention: Prospectus Department or by
email at dg.prospectus_requests@bofa.com; or by accessing the SEC’s
website at www.sec.gov.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Relay Therapeutics
Relay Therapeutics is a clinical-stage precision medicine
company transforming the drug discovery process by combining
leading-edge computational and experimental technologies with the
goal of bringing life-changing therapies to patients. As the first
of a new breed of biotech created at the intersection of
complementary techniques and technologies, Relay Therapeutics aims
to push the boundaries of what’s possible in drug discovery. Its
Dynamo® platform integrates an array of leading-edge computational
and experimental approaches designed to drug protein targets that
have previously been intractable or inadequately addressed. Relay
Therapeutics’ initial focus is on enhancing small molecule
therapeutic discovery in targeted oncology and genetic disease
indications.
Cautionary Note Regarding Forward-Looking
Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended, including, without limitation, statements
regarding Relay Therapeutics’ anticipated public offering. The
words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,”
“anticipate,” “intend,” “believe,” “estimate,” “predict,”
“project,” “potential,” “continue,” “target” and similar
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words.
Any forward-looking statements in this press release, such as
the intended offering terms, are based on management's current
expectations and beliefs and are subject to a number of risks,
uncertainties and important factors that may cause actual events or
results to differ materially from those expressed or implied by any
forward-looking statements contained in this press release,
including, without limitation, uncertainties related to market
conditions and the completion of the public offering on the
anticipated terms or at all. These and other risks and
uncertainties are described in greater detail in the section
entitled “Risk Factors” in Relay Therapeutics’ most recent annual
report on Form 10-K and quarterly report on Form 10-Q filed with
the SEC, as well as discussions of potential risks, uncertainties,
and other important factors in Relay Therapeutics’ other filings
with the SEC, including those contained or incorporated by
reference in the preliminary prospectus supplement and accompanying
prospectus related to the proposed public offering to be filed with
the SEC. Any forward-looking statements contained in this press
release represent Relay Therapeutics’ views only as of the date
hereof and should not be relied upon as representing its views as
of any subsequent date. Relay Therapeutics explicitly disclaims any
obligation to update any forward-looking statements, except as
required by law. No representations or warranties (expressed or
implied) are made about the accuracy of any such forward-looking
statements.
Contact:Megan
Goulart617-545-5526mgoulart@relaytx.com
Media:Dan
Budwick1AB973-271-6085dan@1abmedia.com
Relay Therapeutics (NASDAQ:RLAY)
過去 株価チャート
から 8 2024 まで 9 2024
Relay Therapeutics (NASDAQ:RLAY)
過去 株価チャート
から 9 2023 まで 9 2024